Amathus Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Amathus Therapeutics General Information

Description

Developer of small-molecule therapeutics designed to improve mitochondrial function. The company's therapeutics help in the treatment of rare lysosomal-storage disorders, enabling healthcare professionals to treat neurodegenerative diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 700 Main Street North
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 700 Main Street North
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amathus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 19-Jul-2025 Completed Out of Business
4. Secondary Transaction - Private Completed Generating Revenue
3. Early Stage VC (Series A1) 25-Mar-2019 Completed Generating Revenue
2. Accelerator/Incubator 14-Nov-2018 $50K $50K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Amathus Therapeutics’s complete valuation and funding history, request access »

Amathus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
Series A
To view Amathus Therapeutics’s complete cap table history, request access »

Amathus Therapeutics Patents

Amathus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4121029-A1 Benzenesulfonamide derivatives as trap1 modulators and uses thereof Inactive 20-Mar-2020
WO-2021188880-A1 Benzenesulfonamide derivatives as trap1 modulators and uses thereof Inactive 20-Mar-2020
EP-4121072-A1 Cyclic sulfonamide derivatives as trap1 modulators and uses thereof Inactive 20-Mar-2020
WO-2021188911-A1 Cyclic sulfonamide derivatives as trap1 modulators and uses thereof Inactive 20-Mar-2020
EP-4121030-A1 Pyridinesulfonamide derivatives as trap1 modulators and uses thereof Inactive 20-Mar-2020 C07D413/12
To view Amathus Therapeutics’s complete patent history, request access »

Amathus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amathus Therapeutics FAQs

  • When was Amathus Therapeutics founded?

    Amathus Therapeutics was founded in 2016.

  • Where is Amathus Therapeutics headquartered?

    Amathus Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Amathus Therapeutics?

    Amathus Therapeutics has 3 total employees.

  • What industry is Amathus Therapeutics in?

    Amathus Therapeutics’s primary industry is Drug Discovery.

  • Is Amathus Therapeutics a private or public company?

    Amathus Therapeutics is a Private company.

  • What is Amathus Therapeutics’s current revenue?

    The current revenue for Amathus Therapeutics is .

  • How much funding has Amathus Therapeutics raised over time?

    Amathus Therapeutics has raised $16.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process